MedTrace Logo

Multicenter Study to Evaluate Efficacy, Tolerability, Safety of Derinat

NCT04149431 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2019-11-04

No results posted yet for this study

Summary

This multicenter prospective double blinded placebo-controlled randomized study is designed to to evaluate clinical efficacy, tolerability and safety of medical product Derinat®, solution for external and local use 0.25% in acute infections of respiratory system in children

Conditions

  • Respiratory Infections in Children

Interventions

DRUG

Derinat

desoxyribonucleate sodium

Sponsors & Collaborators

  • PharmPak, LLC

    lead INDUSTRY

Principal Investigators

  • Irina Gerasimova, Dr. · PharmPak, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-15
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04149431 on ClinicalTrials.gov